PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays

Urothelial bladder cancer (UBC) patients ineligible to platinum-based chemotherapy can be treated with immune-checkpoint inhibitors (ICI) in Programmed Death Ligand 1 (PD-L1) positive cases. Although concordance exists between different PD-L1 assays, little is known on PD-L1 expression variability i...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Joep J., Stoop, Hans, Boormans, Joost L., van Leenders, Geert J.L.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516767/
https://www.ncbi.nlm.nih.gov/pubmed/33909149
http://dx.doi.org/10.1007/s00428-021-03094-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516767/
https://www.ncbi.nlm.nih.gov/pubmed/33909149
http://dx.doi.org/10.1007/s00428-021-03094-6

Ejemplares similares